Sign up for our Weekly Checkup Newsletter
Back to News
Blog archive · Segments

Diagnostic Tools EBITDA Multiples: Abcam PLC Acquired by Danaher (~29x 2023 EBITDA)

Updated 1 min read

On August 28th, 2023, life sciences giant Danaher Corporation announced its acquisition of Abcam plc, a leading provider of research antibodies and proteins, for a hefty $5.7 billion (total enterprise value). The deal marks a significant move for Danaher as it seeks to strengthen its foothold in the growing life sciences research market. Danaher paid $24.00 per share for Abcam, translating to a price-to-EBITDA multiple of around 29x estimated 2023 EBITDA, per the fairness opinion, and ~22.4x estimated 2024 EBITDA of $266m.

Diagnostic Tools EBITDA Multiples

The implied multiple was on the high end of the range compared to other diagnostics and life sciences tools companies.

Abcam Acquisition by Danaher
Diagnostics / Life Sciences EBITDA Multiples

The high-end multiple is likely primarily a factor of Abcam's elevated margins and lofty projected growth. According to the fairness opinion, Abcam's EBITDA is expected to grow at a 21.6% compound annual growth rate over the next five years.

Table of Abcam's revenue and adjusted EBITDA projections from the fairness opinion, 2022 actual through 2028 estimated, in millions of dollars

About Scope Research

The Scope Research Healthcare M&A Valuation Database currently has financial details for 180 diagnostics and life sciences deals going back to 2010, 77 of which include reported EBITDA multiples. The diagnostics / life sciences database can be purchased individually, while our affordable annual subscriptions provide access to all of our healthcare M&A databases and segments, updated continuously.

Don't hesitate to reach out to Will Hamilton at will@scoperesearch.co with questions about your specific situation.